There is the potential for other combinations of oncogenes because 73.9% of NSCLC patients expressed a minimum of one gene alteration in genes such as EGFR, ALK, ERBB2, MET, BRAF, ROS1 and RET [19]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.